Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Entyvio“
Suchtreffer
Begriffe & Kennungen
Entyvio · 4.5 · Vaccinations
Eintrag öffnenEntyvio · 4.5 · Vaccinations
Eintrag öffnenEntyvio · 4.5 · Vedolizumab has been studied in adult ulcerative colitis and Crohn’s disease patients with concomitant adminis
Eintrag öffnenEntyvio · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenEntyvio · 4.6 Fertility, pregnancy and lactation · 2
Eintrag öffnenEntyvio · 4.8 Undesirable effects · 1
Eintrag öffnenEntyvio · 4.8 Undesirable effects · 2
Eintrag öffnenEntyvio · 4.8 · 26 System organ class Frequency Adverse reactions Hepatobiliary disorders Common Liver enzyme increased Very r
Eintrag öffnenEntyvio · 4.8 · 27 In clinical studies with intravenous and subcutaneous vedolizumab, the rate of infections in vedolizumab-tr
Eintrag öffnenEntyvio · 4.8 · 7 Tabulated list of adverse reactions
Eintrag öffnenEntyvio · 4.8 · 8 System organ class Frequency Adverse reactions Musculoskeletal and connective Very common Arthralgia tissue
Eintrag öffnenEntyvio · 4.8 · 9 In the EARNEST controlled study (pouchitis) with intravenous vedolizumab, only 1 out of 51 subjects (2.0%) i
Eintrag öffnenEntyvio · 4.8 · Description of selected adverse reactions
Eintrag öffnenEntyvio · 4.8 · Description of selected adverse reactions
Eintrag öffnenEntyvio · 4.8 · In EARNEST controlled study (pouchitis) with intravenous vedolizumab, hypersensitivity reactions, including IR
Eintrag öffnenEntyvio · 4.8 · In GEMINI 1 and 2 controlled studies (ulcerative colitis and Crohn’s disease) with intravenous vedolizumab, th
Eintrag öffnenEntyvio · 4.8 · In GEMINI 1 and 2 controlled studies (ulcerative colitis and Crohn’s disease), 4% of intravenous vedolizumab-t
Eintrag öffnenEntyvio · 4.8 · In GEMINI 1 and 2 controlled studies with intravenous vedolizumab, the rate of infections was 0.85 per patient
Eintrag öffnenEntyvio · 4.8 · In GEMINI 1 and 2 controlled studies with intravenous vedolizumab, the rate of serious infections was 0.07 per
Eintrag öffnenEntyvio · 4.8 · In GEMINI 1 and 2 controlled studies with intravenous vedolizumab, the rate of serious infections was 0.07 per
Eintrag öffnen